WallSt Focus
Total 414 Posts
Applied UV CEO, Max Munn Discusses Company Strategy, Expansion, and Growth Potential
SmallCaps Daily sits down with Applied UV CEO, Max Munn to dicuss company stratgegy, upcoming milestones, and more.
Longeveron Congratulates Co-Founder and Chairman Dr. Joshua Hare on Induction as Fellow of National Academy of Inventors
Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, announced today that Chairman, Co-founder and Chief Science Officer Joshua Hare, MD, FACC, has been inducted as a fellow of the prestigio...
Amesite’s CEO Ann Marie Sastry Special Guest in ARK Invest’s Podcast
Amesite Inc. (NASDAQ: AMST), a leading artificial intelligence software company offering a cloud-based learning platform for education, business, and government markets, announces today that Dr. Ann Marie Sastry participated as a special guest in an ARK Invest Podcast hosted by Cathie Wood of ARK...
The Mirage of Employment Data: Why Federal Policy May Lead Us Toward Deflation
The latest non-farm payroll data has sparked much debate about the direction of our economy. However, an argument could be made that we should be cautious about using such indicators as a gauge for financial policy. A closer examination of these numbers, particularly in light of recent pandemic-r...
Investor Anxiety Peaks as VIX Index Skyrockets Amid Fed Rate Hike Concerns
On Thursday, we saw better-than-expected economic data that further fueled market expectations of rate hikes. June witnessed an impressive addition of 497,000 new payrolls, well above the forecast.
Strong US Jobs Data Spooks Markets: Expectations for Further Rate Hikes Loom
The US labor market has shown continued signs of resilience, as evidenced by the latest job figures.
Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs
SHELTON, CONNECTICUT - July 6, 2023 - NanoViricides, Inc. (NYSE American: NNVC) reports that the clinical trial of its broad-spectrum antiviral drug NV-CoV-2 is progressing satisfactorily.